Infigratinib
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
Product Specifications
CAS Number
[872511-34-7]
Product Name Alternative
BGJ-398; NVP-BGJ398
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; FGFR
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NVP-BGJ398.html
Purity
99.82
Solubility
DMSO : 12 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O
Molecular Formula
C26H31Cl2N7O3
Molecular Weight
560.48
Precautions
H302, H315, H319, H335
References & Citations
[1]Guagnano V, et al. Discovery of 3- (2,6-Dichloro-3,5-dimethoxy-phenyl) -1-{6-[4- (4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T|[2]Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12 (5) :632-42.|[3]Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8 (3) :354-369.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Ann Rheum Dis. 2016 May;75 (5) :883-90. |Anti-Cancer Drug. 2022 Dec.|Biochim Biophys Acta Mol Basis Dis. 2025 May 29:167940.|Biomed Pharmacother. 2025 Oct 21:192:118677.|Biomedicines. 2023 Nov 27;11 (12) :3155.|bioRxiv. 2024 May 14.|bioRxiv. 2025 Jun 16:2025.06.11.659120.|Biotechnol J. 2024 Aug;19 (8) :e2400278.|Cancer Discov. 2018 Mar;8 (3) :354-369.|Cancer Discov. 2019 Dec;9 (12) :1686-1695.|Cancers (Basel) . 2024 Jul 3;16 (13) :2447.|Cell Death Dis. 2025 Jul 2;16 (1) :485.|Cell Rep. 2024 Dec 30;44 (1) :115116.|Cell Rep. 2019 Feb 12;26 (7) :1709-1717.e3. |Chem Res Toxicol. 2021 Jul 19;34 (7) :1800-1813.|Department Biologie. Friedrich-Alexander University Erlangen-Nuremberg. March.10th.2016.|Development. 2025 May 15;152 (10) :dev204687. |FEBS Open Bio. 2023 May;13 (5) :804-817.|Heliyon. 2024 May 10.|J Control Release. 2018 Sep 28;286:254-263.|J Exp Clin Cancer Res. 2021 Aug 27;40 (1) :273.|J Med Chem. 2025 Mar 13;68 (5) :5907-5925.|J Neuroinflammation. 2023 Jan 17;20 (1) :10.|medRxiv. 2023 Mar 17.|Nat Commun. 2022 Aug 4;13 (1) :4534.|Nature. 2022 Aug;608 (7923) :609-617.|NPJ Precis Oncol. 2021 Jul 16;5 (1) :66.|Obesity (Silver Spring) . 2019 Mar;27 (3) :399-408.|Oncogene. 2016 Apr 28;35 (17) :2247-65.|Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20220175722A1.|Pharmaceutics. 2025 Oct 31;17 (11) :1415.|Res Sq. 2025 Jul 24.|RSC Adv. 2020,10, 16231-16244.|Sci Rep. 2016 Apr 28;6:25272.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2025 Nov 3;10 (1) :360.|Signal Transduct Target Ther. 2025 Nov 4;10 (1) :361.|The 22nd National Graduate Research Conference. 2021 Mar 25.|Thorac Cancer. 2025 Jan;16 (1) :e15488.|Tissue Eng Part A. 2019 Mar;25 (5-6) :437-445.|University of Auckland. 2025.|World J Exp Med. 2025 Jun 20;15 (2) :100443.|bioRxiv. 2025 Nov 14.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS8434018-01 0.01 mg
Mouse Cochlin LCCL domain Recombinant Protein DDDDK Tag Lyophilized
Ask
View Details MBS8434018-02 5x 0.01 mg
Mouse Cochlin LCCL domain Recombinant Protein DDDDK Tag Lyophilized
Ask
View Details 